Melanoma (stage III or IV) - ipilimumab: consultee and commentator comments on the ACD
Melanoma (stage III or IV) - ipilimumab: Bristol Myers-Squibb
Melanoma (stage III or IV) - ipilimumab: Bristol Myers-Squibb - supplementary letter
Melanoma (stage III or IV) - ipilimumab: British Association Skin Cancer Specialist Nurses
Melanoma (stage III or IV) - ipilimumab: British Association of Dermatologists
Melanoma (stage III or IV) - ipilimumab: Department of Health
Melanoma (stage III or IV) - ipilimumab: Factor 50
Melanoma (stage III or IV) - ipilimumab: Myfanwy Townsend Melanoma Research Fund
Melanoma (stage III or IV) - ipilimumab: Royal College of Nursing
Melanoma (stage III or IV) - ipilimumab: Royal College of Pathologists
Melanoma (stage III or IV) - ipilimumab: Royal College of Physicians joint NCRI Melanoma Group/RCR/ACP/JCCO
Melanoma (stage III or IV) - ipilimumab: Skcin: The Karen Clifford Skin Cancer Charity
Melanoma (stage III or IV) - ipilimumab: Joint response from Skcin, Factor 50 and the Myfanwy Townsend Melanoma Research
Melanoma (stage III or IV) - ipilimumab: Liverpool reviews and implementation group
This page was last updated: 01 November 2012